Growth hormone in IVF cycles: any hope?

Roger J. Hart, Luk Rombauts, Robert J. Norman

    Research output: Contribution to journalReview articlepeer-review

    24 Citations (Web of Science)


    PURPOSE OF REVIEW: Growth hormone (GH) has been used as an adjunct in ovulation induction and IVF for 25 years, particularly as an adjunct to ovarian stimulation for women who had a previous poor response to stimulation in an IVF cycle. It does not have US Food and Drug Administration approval for this use. Unfortunately, due to the problems inherent with recruiting women who have undergone unsuccessful IVF treatment cycles and their inevitable low live birth rate per initiated cycle, many studies performed to date have been underpowered. RECENT FINDINGS: Previous meta-analyses of studies performed in populations of women with a poor response to ovarian stimulation, demonstrated an increase in the live birth rate for the use of GH. With the recent publication of three studies and the presentation of the Australian LIGHT study, we undertook an updated meta-analysis. SUMMARY: Meta-analysis demonstrated a benefit for the use of the adjunct GH, with a reduction in the duration of ovarian stimulation required for oocyte retrieval, the collection of a greater number of oocytes than placebo, and an improvement in many of the early clinical parameters; however, there was no evidence of an increased chance of a live birth for the use of GH.

    Original languageEnglish
    Pages (from-to)119-125
    Number of pages7
    JournalCurrent Opinion in Obstetrics and Gynecology
    Issue number3
    Publication statusPublished - Jun 2017


    Dive into the research topics of 'Growth hormone in IVF cycles: any hope?'. Together they form a unique fingerprint.

    Cite this